<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immunovia Publ Ab — News on 6ix</title>
<link>https://6ix.com/company/immunovia-publ-ab</link>
<description>Latest news and press releases for Immunovia Publ Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 02 Apr 2025 06:39:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immunovia-publ-ab" rel="self" type="application/rss+xml" />
<item>
<title>Immunovia publishes the Annual Report for 2024</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovia-publishes-annual-report-2024-063900283</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovia-publishes-annual-report-2024-063900283</guid>
<pubDate>Wed, 02 Apr 2025 06:39:00 GMT</pubDate>
<description>Immunovia AB (publ) today announced that the Annual Report for 2024 has been published.</description>
</item>
<item>
<title>The exercise period for warrants series TO 3 begins today</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/exercise-period-warrants-series-3-064400184</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/exercise-period-warrants-series-3-064400184</guid>
<pubDate>Tue, 01 Apr 2025 06:44:00 GMT</pubDate>
<description>Today, 1 April 2025, the exercise period for warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 15 April 2025.</description>
</item>
<item>
<title>Immunovia announces determined exercise price for warrants series TO 3</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovia-announces-determined-exercise-price-202600962</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovia-announces-determined-exercise-price-202600962</guid>
<pubDate>Thu, 27 Mar 2025 20:26:00 GMT</pubDate>
<description>Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24. The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025. The last day for trading in the warrants is 11 April 2025.</description>
</item>
<item>
<title>Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovia-provides-further-positive-data-153100481</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovia-provides-further-positive-data-153100481</guid>
<pubDate>Mon, 24 Mar 2025 15:31:00 GMT</pubDate>
<description>Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially.</description>
</item>
<item>
<title>Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovia-host-webcast-share-more-123800800</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovia-host-webcast-share-more-123800800</guid>
<pubDate>Fri, 21 Mar 2025 12:38:00 GMT</pubDate>
<description>Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.</description>
</item>
<item>
<title>Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovia-announces-another-successful-clinical-122800525</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovia-announces-another-successful-clinical-122800525</guid>
<pubDate>Wed, 19 Mar 2025 12:28:00 GMT</pubDate>
<description>Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of stage I and II cases of pancreatic cancer.</description>
</item>
<item>
<title>Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovias-clariti-study-results-selected-074800654</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovias-clariti-study-results-selected-074800654</guid>
<pubDate>Mon, 03 Mar 2025 07:48:00 GMT</pubDate>
<description>Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week® (DDW) 2025 conference, taking place May 5, 2025.</description>
</item>
<item>
<title>Immunovia Publishes Full Year Report for 2024</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovia-publishes-full-report-2024-074800581</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovia-publishes-full-report-2024-074800581</guid>
<pubDate>Tue, 25 Feb 2025 07:48:00 GMT</pubDate>
<description>Immunovia Publishes Full Year Report for 2024</description>
</item>
<item>
<title>Immunovia initiates search for a new CFO to support commercialization in the USA</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/immunovia-initiates-search-cfo-support-170300039</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/immunovia-initiates-search-cfo-support-170300039</guid>
<pubDate>Fri, 21 Feb 2025 17:03:00 GMT</pubDate>
<description>Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that it will be hiring a new Chief Financial Officer (CFO) as its focus turns to the US market.</description>
</item>
<item>
<title>Invitation to Immunovia's Q4 presentation</title>
<link>https://6ix.com/company/immunovia-publ-ab/news/invitation-immunovias-q4-presentation-090400786</link>
<guid isPermaLink="true">https://6ix.com/company/immunovia-publ-ab/news/invitation-immunovias-q4-presentation-090400786</guid>
<pubDate>Fri, 21 Feb 2025 09:04:00 GMT</pubDate>
<description>Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com.</description>
</item>
</channel>
</rss>